Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innocoll completes dosing in Phase III surgical site infections trial
Innocoll, a biopharmaceutical company, has reported that the last patient has been dosed in the first of two ongoing US Phase III clinical trials sponsored by its wholly
Innocoll, a biopharmaceutical company, has reported that the last patient has been dosed in the first of two ongoing US Phase III clinical trials sponsored by its wholly
According to OrSense, the NBM-200MP system offers for the first time a non-invasive, continuous and accurate measurement of oxygen saturation in states of hypovolemia, hypothermia and vasoconstriction or
The validity of the German patent is being challenged by Medela, Molnlycke Health Care, and Smith & Nephew. The decision is not final and KCI and Wake Forest
According to Flexible Stenting Solutions, this next-generation femoropopliteal stent and delivery system can significantly improve patient care in the high growth peripheral vascular segment. The fully connected flexible
Durect, a specialty pharmaceutical company, has announced positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of Transdur-sufentanil, a seven day patch under
Shire, a specialty biopharmaceutical company, has decided to withdraw the European marketing authorization application for Daytrana for the treatment of attention deficit hyperactivity disorder. A request from European
The company reported net revenues of $11.15 million for the first quarter ended February 28, 2009, a 28% increase, compared to $8.69 million for the same period of
For the nine-month period ended January 31, 2009, the company reported a net loss of $1.02 million, or $0.03 per basic and diluted share, compared to a net
For the year ended December 31, 2008, the company reported a net loss of $14.37 million, or $1.09 per share, an increase of 31%, compared with a net
Under the terms of the three-year, renewable agreement with EKR, ProStrakan will receive undisclosed payments based on the volume of packs of Gelclair that are sold in the